Menu Search
Equities

electroCore, Inc.

43E0:MUN

electroCore, Inc.

Actions
  • Price (EUR)6.55
  • Today's Change-0.300 / -4.38%
  • Shares traded-1.00
  • 1 Year change+16.96%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.

  • Revenue in USD (TTM)18.69m
  • Net income in USD-16.47m
  • Incorporated2005
  • Employees68.00
  • Location
    electroCore, Inc.200 FORGE WAY, SUITE 205ROCKAWAY 07866United StatesUSA
  • Phone+1 (973) 290-0097
  • Fax+1 (973) 290-9171
  • Websitehttps://www.electrocore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.